Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ayala Pharmaceuticals Inc ADXS

Healthcare Biotechnology
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia... see more

Recent & Breaking News (PINL:ADXS)

Advaxis Reports Third Quarter Ended July 31, 2020 Financial Results and Provides a Business Update

GlobeNewswire September 10, 2020

Advaxis Announces Resignation of Chief Financial Officer

GlobeNewswire September 4, 2020

LD Micro - 360 Companies Set to Present this Week

Accesswire August 31, 2020

Advaxis to Present Corporate Overview at the LD Micro 500 Virtual Conference

GlobeNewswire August 27, 2020

LD Micro Announces Preliminary List of Presenters for the LD 500

Accesswire August 5, 2020

Advaxis Announces Common Stock Purchase Agreement for up to $20 Million with Lincoln Park Capital

GlobeNewswire August 3, 2020

Advaxis to be Featured in "Grand Rounds: a Webinar in Biotech and Specialty Pharma," Hosted by Alliance Global Partners

GlobeNewswire June 23, 2020

Advaxis Reports Second Quarter Ended April 30, 2020 Financial Results and Provides a Business Update

GlobeNewswire June 11, 2020

Advaxis to Host Second Quarter Financial Results and Business Update Conference Call on Thursday, June 11, 2020

GlobeNewswire June 1, 2020

Advaxis Announces Updated Positive Clinical and Biomarker Data from Ongoing Phase 1/2 ADXS-503 Trial in NSCLC

GlobeNewswire May 14, 2020

Advaxis Reports First Quarter Ended January 31, 2020 Financial Results and Provides a Pipeline Update

GlobeNewswire March 13, 2020

Advaxis to Present at the 2020 LD Micro Virtual Conference

GlobeNewswire March 3, 2020

Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at I/O 360° Conference

GlobeNewswire February 27, 2020

Advaxis Announces Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at the IASLC 2020 Targeted Therapies of Lung Cancer Meeting

GlobeNewswire February 20, 2020

Advaxis Announces Updated Survival Data in Phase 1/2 ADXS-PSA Trial at the ASCO Genitourinary Cancers Symposium

GlobeNewswire February 13, 2020

Advaxis and Personalis Announce Research Agreement to Deploy ImmunoID NeXT Platform in the ADXS-503 Clinical Program

GlobeNewswire February 11, 2020

Data on Advaxis' Clinical Programs to be Presented at Upcoming Medical Meetings

GlobeNewswire January 30, 2020

Advaxis, Inc. Announces Pricing of $10.5 Million Registered Direct Offering

GlobeNewswire January 21, 2020

Advaxis Announces FDA Clearance of IND for ADXS-504 for Treatment of Prostate Cancer

GlobeNewswire January 7, 2020

Advaxis Reports Fiscal Year 2019 Financial Results and Provides a Business Update

Business Wire December 20, 2019